The FDA has given premarket approval to the 3D breast-imaging technology of Siemens Healthineers' Mammomat B.brilliant mammography platform.
The Mammomat B.brilliant platform was already FDA approved for full-field digital mammography, breast biopsy and titanium contrast-enhanced mammography, according to a Sept. 30 news release from Siemens Healthineers.
Three-dimensional breast imaging, or tomosynthesis, was found to detect cancer at a higher rate than mammography in a recent study.
Read the full Siemens Healthineers' news release here.